Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients.
Sawada Y, Yoshikawa T, Ofuji K, Yoshimura M, Tsuchiya N, Takahashi M, Nobuoka D, Gotohda N, Takahashi S, Kato Y, Konishi M, Kinoshita T, Ikeda M, Nakachi K, Yamazaki N, Mizuno S, Takayama T, Yamao K, Uesaka K, Furuse J, Endo I, Nakatsura T.
Sawada Y, et al. Among authors: tsuchiya n.
Oncoimmunology. 2016 Jan 19;5(5):e1129483. doi: 10.1080/2162402X.2015.1129483. eCollection 2016 May.
Oncoimmunology. 2016.
PMID: 27467945
Free PMC article.